Pulsatile Subcutaneous Hydrocortisone Replacement in Primary Adrenal Insufficiency

Abstract

Pulsatile endogenous cortisol secretion is critical for physiological glucocorticoid gene signaling. Conventional glucocorticoid replacement therapy does not mimic endogenous cortisol pulsing in primary adrenal insufficiency. In an open-labeled, two-week, nonrandomized cross-over study of five patients with adrenal insufficiency (Addison’s disease in two, bilateral adrenalectomy in one, and congenital adrenal hyperplasia in two patients) we compared pulsatile and continuous cortisol pump treatment and conventional oral glucocorticoid therapy with respect to 24-h serum corticosteroid levels and plasma adrenocorticotropic hormone (ACTH). Pulsed pump restored ultradian rhythmicity as demonstrated by five peaks of serum (all patients) and subcutaneous tissue cortisol (four patients). Morning subcutaneous cortisol and cortisone were higher in continuous and pulsed pump treatment than in oral therapy despite nearly similar serum cortisol levels in all treatment arms. ACTH was within the physiological range during pulsed pump treatment in all patients except for slightly elevated levels in the morning hours 04:00–08:00 h. During oral therapy, ACTH was very high in patients with Addison’s disease and suppressed in patients with congenital adrenal hyperplasia. In conclusions, mimicking endogenous cortisol rhythmicity by ultradian subcutaneous infusion of cortisol is feasible. It was superior to both continuous pump and oral therapy in maintaining normal ACTH levels throughout the 24-h cycle. Our results demonstrate a low free cortisol bioavailability on thrice daily oral replacement therapy compared to both types of subcutaneous infusion.

Key words

circadian rhythm - ultradian rhythm - free cortisol - primary adrenal failure - glucocorticoid replacement therapy

Publication History

Received: 28 August 2022

Accepted after revision: 12 May 2023

Accepted Manuscript online:
12 May 2023

Article published online:
10 July 2023

• References

• 1 Selmaoui B, Touitou Y. Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci 2003; 73: 3339-3349
• 2 Lightman LS, Wiles CC, Atkinson HC. et al. The significance of glucocorticoid pulsatility. Eur J Pharmacol 2008; 583: 255-262
• 3 Veldhuis JD, Iranmanesh A, Lizarralde G. et al. Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. Am J Physiol 1989; 257: E6-E14
• 4 Weitzman ED, Fukushima D, Nogeire C. et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971; 33: 14-22
• 5 Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci 2010; 11: 710-718
• 6 Stavreva DA, Wiench M, John S. et al. Ultradian hormone stimulation induces glucocorticoid receptor mediated pulses of gene transcription. Nat Cell Biol 2009; 11: 1093-1102
• 7 Lightman SL, Birnie MT, Conway-Campbell BL. dynamics of ACTH and cortisol secretion and implications for disease. Endocr Rev 2020; 40: 470-490
• 8 Venneri MA, Hasenmajer V, Fiore D. et al. Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study. J Clin Endocrinol Metab 2018; 103: 2998-3009
• 9 Sævik ÅB, Wolff AB, Björnsdottir S. et al. Potential transcriptional biomarkers to guide glucocorticoid replacement in autoimmune Addison’s disease. J Endocr Soc 2021; 5: bvaa202
• 10 Debono M, Price JN, Ross RJ. Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab 2009; 23: 221-232
• 11 Jung C, Greco S, Nguyen HH. et al. Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers. BMC Endocr Disord 2014; 14: 91-98
• 12 Løvås K, Curran S, Oksnes M. et al. Development of a disease-specific quality of life questionnaire in Addison’s disease. J Clin Endocrinol Meta 2010; 95: 545-551
• 13 Mazziotti G, Formenti AM, Frara S. et al. Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 2017; 177: R231-R248
• 14 Øksnes M, Björnsdottir S, Isaksson M. et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison’s disease: a randomized clinical trial. J Clin Endocrinol Metab 2014; 99: 1665-1674
• 15 Kalafatakis K, Russell GM, Harmer CJ. et al. Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man. Proc Natl Acad Sci USA 2018; 115: E4091-E4100
• 16 McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263
• 17 Øksnes M, Bensing S, Hulting AL. et al. Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab 2012; 97: 568-576
• 18 Bhake RC, Leendertz JA, Linthorst AC. Automated 24-hours sampling of subcutaneous tissue free cortisol in humans. J Med Eng Technol 2013; 37: 180-184
• 19 Løvås K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison’s disease. Eur J Endocrinol 2007; 157: 109-112
• 20 Mah PM, Jenkins RC, Rostami-Hodjegan A. et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2004; 61: 367-375
• 21 Methlie P, Hustad SS, Kellmann R. et al. Multisteroid LC-MS/MS assay for glucocorticoids and androgens, and its application in Addison’s disease. Endocr Connect 2013; 2: 125-136
• 22 Russell GM, Durant C, Ataya A. et al. Subcutaneous pulsatile glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 2014; 81: 289-293
• 23 Debono M, Ghobadi C, Rostami-Hodjegan A. et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009; 94: 1548-1554
• 24 Tunn S, Möllmann H, Barth J. et al. Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem 1992; 38: 1491-1494
• 25 Aardal E, Holm AC. Cortisol in saliva–reference ranges and relation to cortisol in serum. Eur J Clin Chem Clin Biochem 1995; 33: 927-932
• 26 Bae YJ, Kratzsch J. Corticosteroid-binding globulin: modulating mechanisms of bioavailability of cortisol and its clinical implications. Best Pract Res Clin Endocrinol Metab 2015; 29: 761
• 27 Droste SK, de Groote L, Atkinson HC. et al. Corticosterone levels in the brain show a distinct ultradian rhythm but a delayed response to forced swim stress. Endocrinol 2008; 149: 3244-3253
• 28 Bhake RC, Kluckner V, Stassen H. et al. Continuous free cortisol profiles-circadian rhythms in healthy men. J Clin Endocrinol Metab 2019; 12: 5935-5947
• 29 Morgan SA, Sherlock M, Gathercole LL. et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009; 58: 2506-2515
• 30 Tomlinson JW, Sinha B, Bujalska I. et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002; 87: 5630-5635
• 31 Arai H, Kobayashi N, Nakatsuru Y. et al. Case of cortisol producing adrenal adenoma without phenotype of Cushing’s syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity. Endocr J 2008; 55: 709-715
• 32 Ceccato F, Selmin E, Sabbadin C. et al. Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr Connect 2018; 7: 965-974
• 33 Johannsson G, Lennernäs H, Marelli C. et al. Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. Eur J Endocrinol 2016; 175: 85-93
• 34 Johannsson G, Nilsson AG, Bergthorsdottir R. et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012; 97: 473-481
• 35 Merza Z, Rostami-Hodjegan A, Memmott A. et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006; 65: 45-50
• 36 Tuli G, Rabbone I, Einaudi S. et al. Continuous subcutaneous hydrocortisone infusion (CSHI) in a young adolescent with congenital adrenal hyperplasia (CAH). J Pediatr Endocrinol Metab 2011; 24: 561-563